These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1278 related articles for article (PubMed ID: 25070148)

  • 1. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
    van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
    Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies.
    Drake MJ; Oelke M; Snijder R; Klaver M; Traudtner K; van Charldorp K; Bongaerts D; Van Kerrebroeck P
    PLoS One; 2017; 12(2):e0170726. PubMed ID: 28166296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis.
    Li MC; Wang ZY; Yang J; Guo XL; Wang T; Wang SG; Liu JH; Ye ZQ
    Asian J Androl; 2015; 17(1):124-34. PubMed ID: 25337836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
    Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
    BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C
    BMC Urol; 2015 May; 15():41. PubMed ID: 25956727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamsulosin/solifenacin fixed-dose combination tablet for the treatment of male lower urinary tract symptoms.
    Romancik M; Pandian S; Drake MJ
    Drugs Today (Barc); 2014 Dec; 50(12):803-11. PubMed ID: 25588085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.
    Shin YS; Zhang LT; You JH; Choi IS; Zhao C; Park JK
    Clin Interv Aging; 2016; 11():1301-1307. PubMed ID: 27698559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving picture of lower urinary tract symptom management.
    Tubaro A; De Nunzio C; Puccini F; Presicce F
    Eur Urol; 2015 Feb; 67(2):271-2. PubMed ID: 25457016
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
    Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
    Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness model of a fixed dose combination of solifenacin and tamsulosin for the treatment of LUTS associated with BPH with inadequate response to monotherapy.].
    Alcántara A; Cózar JM; Errando C; Rubio-Rodríguez D; Rubio-Rodríguez D; Rubio-Terrés C; Mora AM; Duran A
    Arch Esp Urol; 2018 Sep; 71(7):595-606. PubMed ID: 30198851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with tamsulosin and solifenacin for male lower urinary tract symptoms with predominant filling symptoms: a new approach to an old problem.
    Angulo JC
    Curr Med Res Opin; 2015 Nov; 31(11):1963-5. PubMed ID: 26368336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin.
    Yang PS; Chen CL; Hou CP; Lin YH; Tsui KH
    Clin Interv Aging; 2018; 13():235-242. PubMed ID: 29445269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
    Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
    Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Dimitropoulos K; Gravas S
    Drug Des Devel Ther; 2015; 9():1707-16. PubMed ID: 25834406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.